...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.
【24h】

Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.

机译：中性粒细胞性小肠结肠炎在紫杉醇/铂类化学疗法治疗的晚期上皮性卵巢癌患者中：一例并文献复习。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Literature data show that neutropenic enterocolitis is a rare but severe complication that can occur in cancer patients treated with chemotherapy and especially with taxanes. CASE REPORT: A 60-year-old woman with stage Illc epithelial ovarian cancer developed neutropenic fever, abdominal pain, severe diarrhoea, nausea, vomiting and oral mucositis one week after the first postoperative cycle of paclitaxel (175 mg/m2 3-hour infusion) plus carboplatin-based chemotherapy. Abdominal X-ray showed diffuse dilatation of the ileal and colonic loops with air/fluid. The patient soon recovered after intensive supportive care. For the second cycle the dose of paclitaxel was reduced by 20%, but nine days later the patient again developed severe neutropenia with fever, abdominal colicky pain, diarrhoea and vomiting. The culture of blood samples collected on admission was found to be positive for Escherichia coli, whereas stools resulted negative for both enteric rods and Clostridium difficile toxin. The patient recovered with intensive supportive care, and chemotherapy was continued with single-agent carboplatin. DISCUSSION: The increasing use of paclitaxel in first-line as well as in the salvage treatment of epithelial ovarian cancer could increase the occurrence of neutropenic enterocolitis in patients with this malignancy. The importance of symptoms such as neutropenic fever, abdominal pain and tenderness and severe diarrhoea should be stressed in patients who receive taxane-based chemotherapy, and intensive supportive care management should be started immediately.
机译：背景：文献资料表明，中性粒细胞减少性小肠结肠炎是一种罕见但严重的并发症，发生在接受化学疗法，尤其是紫杉烷类药物治疗的癌症患者中。病例报告：紫杉醇的第一个术后周期（175 mg / m2 3小时输注）后一周，一名患有Illc上皮性卵巢癌的60岁女性出现中性粒细胞减少，腹痛，严重腹泻，恶心，呕吐和口腔粘膜炎。 ）加上基于卡铂的化疗。腹部X线检查显示回肠和结肠loop弥漫性扩散，并伴有空气/液体。重症支持治疗后患者很快康复。对于第二个周期，紫杉醇的剂量减少了20％，但是9天后，患者再次出现严重的中性粒细胞减少，伴有发烧，腹部绞痛，腹泻和呕吐。发现入院时采集的血液样本培养物对大肠杆菌呈阳性，而粪便对肠棒和艰难梭菌毒素均呈阴性。患者在重症支持治疗后康复，单药卡铂继续化疗。讨论：紫杉醇在一线卵巢癌中的越来越多的使用以及在上皮性卵巢癌的挽救性治疗中可能增加这种恶性肿瘤患者中性粒细胞减少性小肠结肠炎的发生率。接受紫杉烷类化学疗法的患者应强调中性粒细胞减少，腹痛，压痛和严重腹泻等症状的重要性，并应立即开始加强支持治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号